Latest News

We will be at BIO Europe in Stockholm. With the capability to shepherd your programme through the entire clinical development journey, talk to us and find out how we can guide you through to those crucial milestones. Get a jump start on meaningful discussion by setting up your CDA now

We are proud to have been trusted by Klaria to partner with them on this important project. Read their full press release here

We are proud that over 14% of our colleagues have been with Simbec-Orion for more than 10 years, 22% have tenure of 5-10 years. Our two longest serving colleagues have been with us for more than 40 years! You can meet one of them, Deborah Evans, Clinic Manager at our Phase I Unit here. Managing Director, […]

Our experience of nearly 30 years conducting clinical trials in patients living with a rare diseases has brought us into contact with many different patient organisations.  Today we were honoured to be joined by Rick Thomson, CEO of Beacon, a UK-based non-profit organisation that is building a united rare disease community to support patient groups. […]

Our last blog post looked at what is required for a clinical trial unit to achieve an MHRA accreditation, including a commitment to the highest safety standards, comprehensive procedures and processes, and capable, experienced teams. The benefits of an MHRA Phase I accredited site, inspected and approved by regulators, remain the same for a patient […]

During a half day seminar in central London, our scientific colleagues heard from members of our independent Drug Development Advisory Board on a range of topics, including how Project Optimus will affect clinical development plans and considerations for statistical design. You can catch up with some of the presentations on our webinar page.

In our latest blog, we discuss the consideration when placing your phase I study in the UK. You may have come across CROs or Phase I Units with an MHRA Phase I accreditation – but what does this mean? The MHRA’s voluntary phase I accreditation scheme is available to organisations conducting phase I trials but […]